Increased anticoagulant activity of warfarin used in combination with doxifluridine.

abstract：PURPOSE:Although irinotecan monotherapy is often used in third-line treatment after the failure of taxanes in Japanese clinical practice, its survival benefit is still unclear. The aim of this study is to investigate the efficacy and safety of irinotecan monotherapy as third-line treatment. METHODS:Clinical data from ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawakami T,Machida N,Yasui H,Kawahira M,Kawai S,Kito Y,Yoshida Y,Hamauchi S,Tsushima T,Todaka A,Yokota T,Yamazaki K,Fukutomi A,Onozawa Y

更新日期：2016-10-01 00:00:00

abstract：:Carboxypeptidase G2 (CPG2) is used when unexpected toxicity or renal failure occurs during high-dose methotrexate therapy. Leucovorin is also administered to antagonise the effects of methotrexate on purine anabolism. To investigate the effects of CPG2 on leucovorin rescue, we incubated the enzyme with both stereoisom...

journal_title：Cancer chemotherapy and pharmacology

authors： Hempel G,Lingg R,Boos J

更新日期：2005-04-01 00:00:00

abstract：:The oral bioavailability of methotrexate is variable and may be dose-dependent. The absorption of 'interval' oral methotrexate, which is given between cycles of chemotherapy, is unknown. The bioavailability of oral methotrexate has been studied in eight patients, acting as their own controls, to assess the effect of s...

journal_title：Cancer chemotherapy and pharmacology

authors： Harvey VJ,Slevin ML,Woollard RC,Johnston A,Barnett MJ,Wrigley PF,Turner P

更新日期：1984-01-01 00:00:00

abstract：PURPOSE:We designed a phase I/II trial of intraperitoneal (IP) docetaxel plus S-1 to determine the maximum tolerated dose (MTD) and recommended dose (RD) and to evaluate its efficacy and safety in gastric cancer patients with peritoneal carcinomatosis (PC). METHODS:Patients with PC confirmed by laparoscopy or laparoto...

journal_title：Cancer chemotherapy and pharmacology

authors： Fushida S,Kinoshita J,Kaji M,Hirono Y,Goda F,Yagi Y,Oyama K,Sudo Y,Watanabe Y,Fujimura T,Society for Study of Peritoneal Carcinomatosis in Gastric Cancer.

更新日期：2013-05-01 00:00:00

abstract：:cis-Diammine-1,1-cyclobutane dicarboxylate platinum II (CBDCA, JM8), an analogue of cisplatin showing reduced toxicity in preclinical studies, was evaluated in 60 patients. Doses were given initially every 3 weeks and escalated from 20 to 520 mg/m2. Following this, doses were given every 4 weeks and escalated from 300...

journal_title：Cancer chemotherapy and pharmacology

authors： Calvert AH,Harland SJ,Newell DR,Siddik ZH,Jones AC,McElwain TJ,Raju S,Wiltshaw E,Smith IE,Baker JM,Peckham MJ,Harrap KR

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:This phase I clinical trial evaluated the safety, tolerability, and pharmacokinetics of high-dose intravenous (i.v.) ascorbic acid as a monotherapy in patients with advanced solid tumors refractory to standard therapy. METHODS:Five cohorts of three patients received i.v. ascorbic acid administered at 1 g/min f...

journal_title：Cancer chemotherapy and pharmacology

authors： Stephenson CM,Levin RD,Spector T,Lis CG

更新日期：2013-07-01 00:00:00

abstract：:GR63178A is the second pentacyclic pyrroloquinone to enter clinical trials as an anticancer drug. We developed a reversed-phase, gradient-elution high-performance liquid chromatography (HPLC) method along with a Bond Elut C2 mini-column sample-preparation technique for the analysis of GR63178A, its 9-hydroxy-metabolit...

journal_title：Cancer chemotherapy and pharmacology

authors： Cummings J,French RC,MacLellan A,Smyth JF

更新日期：1991-01-01 00:00:00

abstract：:Severe, debilitating nausea and vomiting are seen in almost 100% of patients treated with cis-platinum. These side-effects can be so severe and prolonged as to preclude therapy in a large number of patients. Commonly used antiemetics have had only limited success in controlling cis-platinum-induced nausea and vomiting...

journal_title：Cancer chemotherapy and pharmacology

authors： Aapro MS,Alberts DS

更新日期：1981-01-01 00:00:00

abstract：:OSI-7836 (4'-thio-beta-D-arabinofuranosylcytosine) is a novel nucleoside analog in phase I clinical development for the treatment of cancer. As with other nucleoside analogs, the proposed mechanism of action involves phosphorylation to the triphosphate form followed by incorporation into cellular DNA, leading to cell ...

journal_title：Cancer chemotherapy and pharmacology

authors： Richardson F,Black C,Richardson K,Franks A,Wells E,Karimi S,Sennello G,Hart K,Meyer D,Emerson D,Brown E,LeRay J,Nilsson C,Tomkinson B,Bendele R

更新日期：2005-03-01 00:00:00

abstract：:We obtained evidence that the cytotoxic effect of 5-fluorouracil (5-FU) is augmented when the drug is given in combination with hyperthermia (HYP) and dipyridamole (DP). Nontoxic levels of DP enhanced the combined cytotoxicity of 5-FU and HYP against B16 melanoma and human tumor cells in vitro as measured by the succi...

journal_title：Cancer chemotherapy and pharmacology

authors： Maehara Y,Sakaguchi Y,Takahashi I,Yoshida M,Kusumoto H,Masuda H,Sugimachi K

更新日期：1992-01-01 00:00:00

abstract：:A randomized controlled clinical trial was conducted to compare the use of farmorubicin (FARM) and adriamycin (ADR) in Lipiodol transcatheter arterial chemoembolization (L-TAE) as a treatment of hepatocellular carcinoma. In all, 192 hospitals participated, and 415 patients were enrolled in the study during the period ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawai S,Tani M,Okamura J,Ogawa M,Ohashi Y,Monden M,Hayashi S,Inoue J,Kawarada Y,Kusano M

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Glutathione S-transferases (GSTs) family of enzymes is best known for their cytoprotective role and their involvement in the development of anticancer drug resistance. Recently, emergence of non-detoxifying properties of GSTs has provided them with significant biological importance. Addressing the complex inter...

journal_title：Cancer chemotherapy and pharmacology

authors： Singh S

更新日期：2015-01-01 00:00:00

abstract：PURPOSE:This study aimed at investigating the anti-tumor effect of arsenic sulfide (As2S2) against liver cancer both in vivo and in vitro and to elucidate its underlying mechanisms. METHODS:Cell viability of the human hepatocellular carcinoma cell lines SMMC-7721, BEL-7402, HepG2 were measured by CCK-8 assay. The effe...

journal_title：Cancer chemotherapy and pharmacology

authors： Wang S,Zhang C,Li Y,Li P,Zhang D,Li C

更新日期：2019-03-01 00:00:00

abstract：:We compared the safety and efficacy in mice with peritoneal carcinomatosis of two etoposide formulations: an aqueous solution (Etp-sol) and particles suspended in oil (the addition products of iodine and the ethyl esters of the fatty acids obtained from poppy-seed oil (Lipiodol) or sesame oil; Etp-oil). We also invest...

journal_title：Cancer chemotherapy and pharmacology

authors： Lee JS,Takahashi T,Hagiwara A,Yoneyama C,Itoh M,Sasabe T,Muranishi S,Tashima S

更新日期：1995-01-01 00:00:00

abstract：:Cisplatin-induced emesis is one of the most feared side effects in cancer treatment. High-dose metoclopramide may prevent only 30-40% of cases of acute emesis. Investigations to test the efficacy of new antiemetics are mandatory. We compared the efficacy, toxicity, and patients' preference for tropisetron, a new 5-hyd...

journal_title：Cancer chemotherapy and pharmacology

authors： Chang TC,Hsieh F,Lai CH,Tseng CJ,Cheng HH,Li CL,Michael BJ,Soong YK

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. Resistant ovarian cancer cells often overexpress bcl-2 or p53 proteins or both. We hypothesized that arsenic compounds, such as As2O3 and As2S3, could also be active...

journal_title：Cancer chemotherapy and pharmacology

authors： Du YH,Ho PC

更新日期：2001-06-01 00:00:00

abstract：:Peripheral blood stem and progenitor cells (PBSC and PBPC), which circulate at very low levels during steady-state hematopoiesis, show a transient but marked increase during hematologic recovery from marrow-suppressive chemotherapy. To ensure rapid and sustained hematologic engraftment after autologous PBSC transplant...

journal_title：Cancer chemotherapy and pharmacology

authors： Harada M,Teshima T,Fujisaki T,Mizuno S,Miyamoto T,Takamatsu Y,Kubota A,Ohno Y,Kuroiwa M,Takenaka K,Eto T,Akashi K,Gondo H,Okamura T,Inaba S,Niho Y

更新日期：1996-01-01 00:00:00

abstract：PURPOSE:Ifosfamide is becoming an important clinical anticancer drug. Meaningful pharmacology studies require quantification of its activated and active metabolites, 4-hydroxyifosfamide (HOIfos) and isophosphoramide mustard (IPM), respectively. METHODS:Current methodology for quantifying the unstable HOIfos in biologi...

journal_title：Cancer chemotherapy and pharmacology

authors： Struck RF,McCain DM,Tendian SW,Tillery KH

更新日期：1997-01-01 00:00:00

abstract：PURPOSE:Idasanutlin, a selective small-molecule MDM2 antagonist in phase 3 testing for refractory/relapsed AML, is a non-genotoxic oral p53 activator. To optimize its dosing conditions, a number of clinical pharmacology characteristics were examined in this multi-center trial in patients with advanced solid tumors. ME...

journal_title：Cancer chemotherapy and pharmacology

authors： Nemunaitis J,Young A,Ejadi S,Miller W,Chen LC,Nichols G,Blotner S,Vazvaei F,Zhi J,Razak A

更新日期：2018-03-01 00:00:00

abstract：PURPOSE:Although treatment of melanoma with BRAF inhibitors and immune checkpoint inhibitors achieves a high response rate, a subset of melanoma patients with intrinsic and acquired resistance are insensitive to these therapeutics, so to improve melanoma therapy other target molecules need to be found. Here, we screene...

journal_title：Cancer chemotherapy and pharmacology

authors： Aida S,Sonobe Y,Yuhki M,Sakata K,Fujii T,Sakamoto H,Mizuno T

更新日期：2017-06-01 00:00:00

abstract：PURPOSE:P-glycoprotein (P-gp), encoded by MDR1 (or ABCB1), is important in anticancer drug delivery and resistance. We evaluated alterations in P-gp-mediated transport of anticancer agents due to the MDR1 G1199A polymorphism. METHODS:Using stable recombinant epithelial cells expressing wild-type (MDR1 (wt)) or G1199A ...

journal_title：Cancer chemotherapy and pharmacology

authors： Woodahl EL,Crouthamel MH,Bui T,Shen DD,Ho RJ

更新日期：2009-06-01 00:00:00

abstract：PURPOSE:Thyroid cancers with unsatisfactory curative effect nowadays are the most common malignant tumors of the endocrine system. Apoptosis evasion, a hallmark of cancer, has driven the search of stimulating novel cell death way in cancer therapy. This review aims to explore the relationship between autophagy and thyr...

journal_title：Cancer chemotherapy and pharmacology

authors： Li LC,Liu GD,Zhang XJ,Li YB

更新日期：2014-03-01 00:00:00

abstract：PURPOSE:Because of the recurrence of hepatocellular carcinoma (HCC) at the graft after liver transplantation, circulating HCC cells may be present during the anhepatic period. Intravenous doxorubicin (DOX) is used during the anhepatic period to combat these cells; however, pharmacokinetics data have been poorly analyze...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi S,Wada H,Hama N,Akita H,Kawamoto K,Eguchi H,Umeshita K,Doki Y,Mori M,Nagano H

更新日期：2013-12-01 00:00:00

abstract：PURPOSE:Troxacitabine (BCH-4556, l-(-)-OddC, Troxatyl) is a novel beta- l-nucleoside analogue with potent antineoplastic activity both in vitro and in several tumor models in vivo, and is presently in phase II clinical trials. The combination of the cytosine analogues troxacitabine and araC (1-beta- d-arabinofuranosylc...

journal_title：Cancer chemotherapy and pharmacology

authors： Bouffard DY,Jolivet J,Leblond L,Hamelin B,Ouellet F,Barbeau S,Richard A,Gourdeau H

更新日期：2003-12-01 00:00:00

abstract：:In a pilot study of cyclical chemotherapy in patients with poor-prognosis non-Hodgkin's lymphoma (NHL), high-dose methotrexate (MTX) 1 g/m2 with folinic acid rescue was given as initial treatment and then between cycles of a single-arm CHOP combination administered every 4 weeks. Of 21 patients with previously untreat...

journal_title：Cancer chemotherapy and pharmacology

authors： Child JA,Barnard DL,Cartwright SC,Lauder I,Simmons AV,Stone J,Thorogood J

更新日期：1983-01-01 00:00:00

abstract：BACKGROUND:Therapeutic approach for patients with metastatic breast cancer (MBC) is still controversial. This study was conducted to assess the efficacy and safety of bevacizumab in combination with docetaxel plus capecitabine as first-line treatment for MBC. The feasibility of bevacizumab maintenance therapy in this s...

journal_title：Cancer chemotherapy and pharmacology

authors： Bisagni G,Musolino A,Panebianco M,De Matteis A,Nuzzo F,Ardizzoni A,Gori S,Gamucci T,Passalacqua R,Gnoni R,Moretti G,Boni C

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:We evaluated the influence of serum cystatin C (CysC) with respect to other glomerular filtration rate (GFR) markers on the treatment effect of everolimus in a phase II study in patients with metastatic renal cell carcinoma (mRCC). MATERIALS AND METHODS:Outcomes were from the study's primary analysis. GFR w...

journal_title：Cancer chemotherapy and pharmacology

authors： Bodnar L,Stec R,Dzierżanowska M,Synowiec A,Cierniak S,Kade G,Szczylik C

更新日期：2016-08-01 00:00:00

abstract：PURPOSE:Acid ceramidase (AC) occupies an important place in the control of cancer cell proliferation. We tested the influence of AC inhibition on the effects of PSC 833, a P-glycoprotein antagonist with potent ceramide-generating capacity, to determine whether AC could be a therapeutic target in pancreatic cancer. MET...

journal_title：Cancer chemotherapy and pharmacology

authors： Morad SA,Messner MC,Levin JC,Abdelmageed N,Park H,Merrill AH Jr,Cabot MC

更新日期：2013-03-01 00:00:00

abstract：:A phase II trial of idarubicin was performed in 24 patients with advanced lymphoma. The drug was administered in a dose of 10-15 mg/m2 i.v. or 15-70 mg/m2 p.o. (single dose) every 3 weeks. There were four partial responses and four minor responses. All but one of the responders had received prior doxorubicin therapy. ...

journal_title：Cancer chemotherapy and pharmacology

authors： Gillies H,Liang R,Rogers H,Harper P,Parapia L,Cox G,Johnson S

更新日期：1988-01-01 00:00:00

abstract：PURPOSE:We report the unexpected absence of early relapse (before 30 months) in 24 consecutive patients with isolated limb primary Ewing sarcoma treated with an intensified pilot protocol, SCMCIE94. METHODS:Clinical data for the study were collected retrospectively from the patient files. The protocol included 6 cours...

journal_title：Cancer chemotherapy and pharmacology

authors： Cohen IJ,Toledano H,Stein J,Kollender Y,Fenig E,Konen O,Bar-Sever Z,Issakov J,Feinmesser M,Avigad S,Ash S

更新日期：2019-05-01 00:00:00